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Purpose:  To examine  “constant  lesion  sharpness”  as a morphological  diagnostic  sign  in  the  differential
diagnosis  between  benign  and malignant  lesions.
Material and  methods:  This  prospective  study  had  institutional  review  board  approval  and  was  HIPAA  com-
pliant.  In total  1014  consecutive  patients  were  examined  (mean  age  55  years  ±  13  years)  and  evaluated  in
our University  hospital  towards  the  morphological  shape  of  the  lesion  borders.  The  “Constant  sharpness
Sign”  was  deﬁned  as a lesion  remaining  continuously  sharp  for  the duration  of  the  dynamic  scan.  Inclu-
sion  criteria  were  unclear  ﬁndings  (e.g.  BIRADS  III/IV),  Preoperative  staging  (BRIDAS  IV/V),  and  referred
patients  from  local  clinic  of gynecology.  Exclusion  criteria  were  MRM-examination  ≤1  year  before,  status
after  surgery  and/or  biopsy,  chemotherapy  and/or  radiation  therapy.  Reference  Standard  was  histolog-
ical  veriﬁcation.  Images  were  diagnosed  by  two experienced  radiologists  in  consensus,  blinded  to the
standard  of  reference.
Results: 1014  patients  with  1084  lesions  (436 benign,  648  malignant  lesions)  were  included  into  the
study.41.5%  of  benign  lesions  and  6.8%  (181/436)  of  malignant  lesions  displayed  a constant  sharpness  as  an
accompanying  morphological  sign  (P  < 0.001).  This  resulted  in  a sensitivity  of 41.5%,  speciﬁcity  of  93.2%,
a  positive  likelihood  ratio of  6.1%,  a negative  likelihood  ratio  of 0.63  and  an odd’s  ratio  of 9,7%.
Summary  and  conclusion:  The  constant  sharpness  sign  seems  to  be an  accurate  predictor  of  benign  breast
lesions,  which  may  help  to increase  the  accuracy  of  MRM as  a morphological  sign.
©  2016  The  Author(s).  Published  by  Elsevier  Ltd. This  is an open  access  article  under  the  CC  BY-NC-ND. Introduction
The current guidelines of the American College of Radiology
ACR) list among the speciﬁc indications for breast MR  (MR-
ammography: MRM)  mainly patients after operation or radiation,
reoperative staging, cancer of unknown primary (CUP Syndrome)
nd genetic disposition (BRCA 1 or 2, etc.) [1]. Although MRM  is
nternationally accepted to be the most accurate imaging tool in
he detection of breast cancer, there is still a broad discussion about
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a general use of MRM  for all women, i.e. screening especially since
speciﬁcity and cost are much disputed [2,3].
Through the introduction of additional diagnostic signs, deﬁn-
ing a lesion and its differential diagnoses such as the Blooming
sign [4], perifocal edema sign [5], the darkness in T2 Sign [6], etc.
the general speciﬁcity of MRM  could be raised to levels above 95%
[3], suggesting that reader experience, and technical standards are
prerequisites for “high-quality”- MRM  [2].
During clinical routine the “Constant sharpness sign” (CS) as
the opposing feature of the Blooming Sign was  discovered to be a
strong hint towards benign lesions. It is deﬁned as a lesion obtain-
ing a sharp contour all through the duration of the dynamic scan
(Figs. 1 and 2).
While the commonly known “blooming sign” is a strong indica-
tor for malignant lesions [4], the diagnostic value of the CS has not
e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Fig. 1. Subtraction 1 and 7 min  of the left breast after the injection of 0,1 mmol  Gd-
DTPA per kg body weight within 10 s, followed by the injection of 30 ml  saline via
an  automatic injector (Medrad, Spectris, Pittsburgh) with 3 ml/s. The lesion in the
medial aspect obtains its smooth margins throughout the duration of the dynamic
scan.
Fig. 2. Subtraction 1, 2 and 7 min  of the right breast after the injection of 0,1 mmol
Gd-DTPA per kg body weight within 10 s, followed by the injection of 30 ml  saline via
an  automatic injector (Medrad, Spectris, Pittsburgh) with 3 ml/s. The lesion margins
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malignant lesions (Table 3) displayed constant sharpness as an
accompanying morphological sign (P < 0.001). There was no signiﬁ-
T
E
an  the medial aspect blooms and becomes unsharp throughout the duration of the
ynamic scan.
een evaluated yet. In an effort to complete this task we  wanted
o answer the question as to whether CS is a reliable indicator for
enign lesions.
. Material and methods
All patients gave their written informed consent for the exam-
nation in this IRB approved prospective study. CS was  deﬁned as
 lesion obtaining continuously sharp margins for the duration of
he dynamic scan, while the shape of the lesion was not relevant,
.e. absence of the “Blooming-Sign”.
able 1
xamination protocol.
Sequence (Nr.) 1. Nat cor 2. Dynamic* tra
Weighting T1 T1 
Puls  sequence FLASH FLASH 
Orientation cor transv 
TR  (ms) 113 113 
TE  (ms) 4,6 4,6 
Flip  angle (◦) 80 80 
Slice  thickness (mm)  3 3 
Gap  (mm)  0 0 
Field  of view (mm)  350 350 
Nr.  of slices 44 44 
Matrix  (Pixels) 230 × 256 307 × 384 
* Connotation: dynamic study before and after the i.v. application of 0,1 mmol  Gd-DTP
utomatic injector (Medrad, Spectris, Pittsburgh) with 3 ml/s.adiology Open 3 (2016) 236–238 237
2.1. Patient collective
The study involved a consecutive number of series of 1014
patients (mean patient age e 55.5 years ± 13.0 years). In total there
were 1084 lesions (436 benign lesions, 648 malignant lesions.
Inclusion criteria were unclear ﬁndings (e.g. BIRADS III), pre-
operative staging (BRIDAS IV/V), referred from local clinic of
gynecology. Exclusion criteria were surgery and/or biopsy, as well
as chemotherapy and/or radiation therapy less than 1 year ago.
Histological veriﬁcation served as reference standard.
2.2. Preparation
Before a planned MRM  examination an extensive patient edu-
cation about risks, the examination itself and contraindications
was conducted, including patient anamnesis (i.e. day of the men-
strual cycle, breastfeeding-, tumor-, hormone- and family history).
Patients under HRT (hormone replacement therapy) were asked
to stop HRT 4 weeks prior the MRM  examination. Directly before
being put into the scanner, the patients were asked to minimize
motion in order to prevent artifacts.
2.3. Image acquisition and interpretation
All MRM  exams were performed with a 1.5 T-MR Scanner
(Siemens Symphony and Avanto) using the following protocol, as
also described in detail in other publications (Table 1) [7].
The MRM  examinations were performed and diagnosed by two
experienced radiologist in consensus (>29 years of experience in
MRM  and >10 years of experience in MRM),  blinded to the standard
of reference.
2.4. Statistical methods
Diagnostic parameters were calculated using the following for-
mulas:
Sensitivity: TP/(TP + FN); Speciﬁcity: TN/(TN + FP); Positive pre-
dictive value: TP/(TP + FP); Negative predictive value: TN/(TN + FN);
Accuracy: (TP + TN)/(TP + FP + FN + TN); Positive likelihood ratio:
Sens./1-Spec.; Negative likelihood ratio: 1-Sens./Spec.
3. Results
1014 patients with 1084 lesions (436 benign, 648 malignant
lesions) were included into the study.
41.5% of benign lesions (Table 2) and 6.8% (181/436) ofcant difference in grading of malignant lesions, i.e. invasive cancers
(Table 4). This resulted in a sensitivity of 41.5%, speciﬁcity of 93.2%,
3. CM cor 4. T2-TSE 5. STIR
T1 T2 T2 (T1, 150 ms)
FLASH TSE TSE
cor transv transv
113 8900 8420
4,6 207 70
80 191 180
3 3 3
0 0 0
350 350 350
44 44 44
230 × 256 435 × 512 326 × 384
A per kg body weight within 10 s, followed by the injection of 30 ml saline via an
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Table 2
Benign lesions showing the Constant sharpness sign (CS).
Diagnosis CS positive [%] 95% Conﬁdence Interval
Fibroadenoma 63.1 (65/103) 53.5–71.8
Phylloid tumor 90.0 (9/10) 59.6–98.2
Papilloma 45.8 (38/83) 35.5–56.5
Inﬂammation 15.0 (3/20) 5.2–36.4
Fibrocystic changes 30.0 (66/220) 24.3–36.4
Total 41.5 (181/436) 37.0–46.2
Table 3
Malignant lesions showing the Constant sharpness sign (CS).
Cancer Type CS positive (%) 95% Conﬁdence Interval
Ductal invasive 4,3 (15/347) 3,7–4,6
Lobular invasive 7,4 (8/108) 3,8–13,9
Ductal and lobular inv. 4,2 (1/24) 0,7–20,2
Tubular 3,7 (1/27) 0,07–18,3
Mucinous 16,7 (1/6) 3,0–56,4
Papillary 50 (1/2) 9,5–90,6
Other 14 (7/47) 7,0–26,2
Total 6,8 (44/648) 5,1–9,0
Table 4
Grading of invasive tumors in relation to the constant sharpness Sign (CS).
Grading CS positive (%) 95% Conﬁdence Interval
G1 - invasive 9,7 (6/62) 4,5–19,6
G2  - Invasive 5,1 (13/253) 3,0–8,6
G3  - Invasive 5,1 (11/217) 2,9–8,9
Table 5
Sensitivity, Speciﬁcity, NPV, PPV and Odds Ratio of CS.
Parameter Value 95% Conﬁdence Interval
Sensitivity 41.5% 37.0–46.2
Speciﬁcity 93.2% 91.0–94.9
Positive likelyhood ratio 6.1% 4.51–8.31
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[8] Pathologie 4. Weibliches Genitale Mamma; Pathologie Der Schwangerschaft,
Der Plazenta Und Des Neugeborenen; Infektionskrankheiten Des Fetus . . .,
Springer, Berlin, 1997.
[9] W.A. Kaiser, Signs in MR-Mammography, 1st ed., Springer, 2008, Corr. 2ndNegative likelyhood ratio 0.63% 0.58–0.68
Diagnostic odds ratio 9.7% 6.8–14.0
 positive likelihood ratio of 6.1%, a negative likelihood ratio of 0.63
nd an odd’s ratio of 9,7% (Table 5).
. Discussion
According to our study “constant sharpness” (CS) represents a
aluable morphological sign in MR-Mammography (MRM). CS may
e considered the counterpart of the “Blooming-Sign” [4] and pre-
enting as an accurate predictor of benignity. Blooming is merely
aused by arterioveneous shunts, known to be responsible for the
inetic wash-in and -out effect. Aside from vessel density, also
ellular density and changes in the extracellular matrix as well
s in hydrostatic pressure seem to affecting the formation of the
Blooming-Sign” as well as CS.
A sensitivity of 41% of CS stretches the fact, that this morpho-
ogical sign may  not be seen in all cases. However, a speciﬁcity of
3.2% and an odds ratio of 9,7% underline its diagnostic power in
he case of its presence. As the differential diagnosis of ﬁbroade-
oma and papilloma may  be considered quite difﬁcult in MRM,  our
tudy revealed constant sharpness to be a rather typical attribute
f ﬁbroadenoma with 63,5% of CS positive cases vs. papilloma with
5% CS positive cases, in line with the data of Fischer et al. [4].
In hypothesis papilloma have a higher stromal vessel density,hich may  lead to extravasation of contrast medium, which in turn
ay  be deported more slowly within the space between instersti-
ium and the intracellular space. Additionally papilloma tend to beadiology Open 3 (2016) 236–238
more associated with dissociated ﬁbrosis (pseudoinﬁltrations) and
sclerosis, leading to the presence of blooming [8].
Along with other predicting morphological and kinetic signs
of papilloma, constant sharpness may  contribute to an improved
differential diagnosis as well as improve the accuracy of MR-
mammography all together.
On a different note however, there were some malignant lesions,
displaying CS as well. Especially 16.7% CS positive mucinous cancers
and 50% CS positive papillary cancers (Table 3) emphasize the fact
that the dynamically constant sharpness of a lesion may  not be con-
sidered a pure sign of benignity. Papillary cancers are usually rich in
parenchyma, lacking stroma, hypothetically making an interstitial
accumulation (blooming) of contrast medium almost impossible
[8].
These morphological and kinetic exceptions hint towards the
necessity for the implementation of as many possible diagnos-
tic signs, when forming a diagnosis and differential diagnosis in
MR-Mammography and points towards the ongoing need for the
scientiﬁc evaluation of additional morphological and kinetic signs
in order to optimize MRM  in its accuracy. It also indicates, that the
common MR-BIRADS descriptors of lesions may  need to be updated,
as many known diagnostic signs [9] known in MR-Mammography
are still not yet scientiﬁcally evaluated.
4.1. Study limitations
Our results were obtained within a single center study and
therefore should be conﬁrmed in a multicenter setting. Also there
is a need to test on constant sharpness with other techniques, using
commonly used 3D techniques with/without fat suppression in
order to evaluate technical differences.
5. Conclusion
The constant sharpness sign (CS) was a strong predictor of
benignity. It seems to be a more typical morphological sign of
ﬁbroadenoma than papilloma.
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